Olumiant is an anti-rheumatic drug owned by Eli Lilly And Co. It contains the active ingredient baricitinib and was first authorized for market use on 31 May, 2018. The drug is available in tablet, oral dosage forms and holds a total of 6 drug patents. None of these drug patents have expired yet.
The generic version of Olumiant could be available after 30 November, 2032, which marks the expiry of the last patent. Drug patent challenges against Olumiant might be filed from 31 May, 2022 onwards.
Olumiant, driven by its active ingredient baricitinib, is employed in the treatment of several conditions including rheumatoid arthritis and severe alopecia areata in adults. It also shows marked effectiveness in the treatment of coronavirus disease (COVID-19) in hospitalized adults who require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Olumiant holds a total of 6 drug patents. None of these have expired as of now. The last patent is set to expire on 30 November, 2032. Below are the details of the patents: